Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06045195
NCT06045195
Not yet recruiting
Phase 2

Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

University of Cologne1 site in 1 country40 target enrollmentAugust 2025
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHodgkin Lymphoma
InterventionsPembrolizumab

Overview

Phase
Phase 2
Intervention
Pembrolizumab
Conditions
Hodgkin Lymphoma
Sponsor
University of Cologne
Enrollment
40
Locations
1
Primary Endpoint
progression free survival
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care

Registry
clinicaltrials.gov
Start Date
August 2025
End Date
January 2029
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Peter Borchmann

Prof.

University of Cologne

Eligibility Criteria

Inclusion Criteria

  • •age 18-60
  • •advanced stage classical Hodgkin Lymphoma
  • •no previous treatment for cHL

Exclusion Criteria

  • •Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
  • •Chemotherapy or radiotherapy in medical history
  • •Prior or concurrent disease that prevents treatment according to protocol

Arms & Interventions

Treatment

Pembrolizumab + BrECADD

Intervention: Pembrolizumab

Outcomes

Primary Outcomes

progression free survival

Time Frame: 1 year

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 2
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaLymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin LymphomaRecurrent Nodular Sclerosis Classical Hodgkin LymphomaRefractory Lymphocyte-Depleted Classical Hodgkin LymphomaRefractory Mixed Cellularity Classical Hodgkin LymphomaRefractory Nodular Sclerosis Classical Hodgkin Lymphoma
NCT03077828Northwestern University43
Active, not recruiting
Phase 2
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerCarcinoma Breast Stage IV
NCT02755272Fox Chase Cancer Center87
Active, not recruiting
Phase 2
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin LymphomaClassical Hodgkin LymphomaLymphocyte-Depleted Classical Hodgkin LymphomaLymphocyte-Rich Classical Hodgkin LymphomaMixed Cellularity Classical Hodgkin LymphomaNodular Sclerosis Classical Hodgkin Lymphoma
NCT03226249Northwestern University30
Recruiting
Phase 1
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)Mesotheliomas Pleural
NCT03760575Abramson Cancer Center at Penn Medicine20
Recruiting
Phase 2
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
NCT06670911Instituto Nacional de Cancer, Brazil44